<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817801</url>
  </required_header>
  <id_info>
    <org_study_id>NFH20190104</org_study_id>
    <nct_id>NCT03817801</nct_id>
  </id_info>
  <brief_title>Comparison of Scoring Balloon and Conventional Balloon Predilation Before Drug Coated Balloon for de Novo Lesion in Patients With High Bleeding Risk</brief_title>
  <acronym>PREPARE-NSE</acronym>
  <official_title>Comparison of Scoring Balloon and Conventional Balloon Predilation Before Drug Coated Balloon for de Novo Lesion in Patients With High Bleeding Risk: A Randomized, Single-center, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate whether scoring balloon (non-slip element, NSE)
      predilation compared to non-compliant (NC) balloon predilation for de novo lesion in patients
      with high bleeding risk and planning to receive drug-coated balloon (DCB) treatment will lead
      to lower change in minimal lumen area (MLA) at 6 months by intravascular ultrasound (IVUS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study that aim to enroll 60 subjects with high bleeding risk.

      All patients with coronary artery stenosis suitable for DCB treatment will undergo 1:1
      randomization either to NSE predilation or NC balloon predilation using a randomization
      schedule.

      All subjects will be screened according to the predefined inclusion and exclusion criteria
      per protocol and will further undergo IVUS before DCB treatment. Data and images will be
      collected during the index procedure, and at the predefined 6-month IVUS follow-up visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will undergo 1:1 randomization to either non-slip element (NSE) predilation which will be the treatment group or non-compliant (NC) balloon predilation which will be the control group. The initiation of the trial is defined as the time of randomization. After study subjects' enrollment and randomization, the study intervention will take place immediately. The follow-up visits for the primary endpoint are scheduled at 1and 6 months after the index procedure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessor will remain blinded until the final study results are released.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The absolute change in minimal lumen area (MLA)</measure>
    <time_frame>6 months</time_frame>
    <description>The absolute change in MLA from post-procedure to 6-month follow-up identified by intravascular ultrasound (IVUS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bailout drug-eluting stents (DES) implantation rate</measure>
    <time_frame>During procedure</time_frame>
    <description>Bailout DES implantation rate during procedure by angiographic criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Flow Reserve (FFR) value</measure>
    <time_frame>immediately after balloon predilation</time_frame>
    <description>FFR value after balloon predilation measured by FFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum lumen area (MLA)</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>MLA after procedure by IVUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum lumen diameter (MLD)</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>MLD after procedure by IVUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque burden</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>Plaque burden after procedure by IVUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dissection</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>Dissection after procedure by IVUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atheroma volume</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>Atheroma volume after procedure by IVUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The diameter stenosis of target lesion</measure>
    <time_frame>6 months</time_frame>
    <description>The diameter stenosis of target lesion from post-procedure to 6-month follow-up by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The late lumen loss of target lesion</measure>
    <time_frame>6 months</time_frame>
    <description>The late lumen loss of target lesion from post-procedure to 6-month follow-up by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The binary restenosis of target lesion</measure>
    <time_frame>6 months</time_frame>
    <description>The binary restenosis of target lesion from post-procedure to 6-month follow-up by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of cardiac death, myocardial infarction, target lesion revascularization (TLR), and target lesion thrombosis</measure>
    <time_frame>6 months</time_frame>
    <description>The composite of cardiac death, myocardial infarction, TLR, and target lesion thrombosis at 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>non-slip element (NSE) predilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the NSE predilation group, NSE predilation will be performed for all lesions preparation before drug-coated balloon (DCB) treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-compliant (NC) balloon predilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the NC balloon predilation group, NC balloon predilation will be performed for all lesions preparation before DCB treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NSE balloon</intervention_name>
    <description>NSE (Goodman®) predilation + DCB (Sequent® Please) treatment</description>
    <arm_group_label>non-slip element (NSE) predilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NC balloon</intervention_name>
    <description>NC balloon predilation + DCB (Sequent® Please) treatment</description>
    <arm_group_label>non-compliant (NC) balloon predilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  De Novo lesion, suitable for intravascular ultrasound (IVUS) and fractional flow
             reserve (FFR) test;

          -  Coronary artery disease (CAD) patients with high risk of bleeding

        Exclusion Criteria:

          -  Previous coronary artery bypass graft (CABG) patients

          -  Stent implantation in the target vessel

          -  Estimated glomerular filtration rate (eGFR) &lt; 30 ml/min/1.73m2

          -  Acute ST segment elevation myocardial infarction (STEMI) within 48 hours

          -  Contraindications to contrast media, antiplatelet therapy, or paclitaxel

          -  Cardiac shock

          -  Pregnancy

          -  Expected life less than 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Liang Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-jie Zhang, MD, PhD</last_name>
    <phone>+86-25-52271350</phone>
    <email>jameszll@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao-Fei Gao, MD, PhD</last_name>
    <phone>+86-25-52271350</phone>
    <email>gaoxiaofei2014@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD</last_name>
      <phone>+86 13605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
    <investigator>
      <last_name>Shaoliang Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>February 2, 2020</last_update_submitted>
  <last_update_submitted_qc>February 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Junjie Zhang</investigator_full_name>
    <investigator_title>Vice Director of Cardiovascular Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

